BioTime, Inc. Share Price NYSE
Stocks
US09066L1052
Biotechnology & Medical Research
| Market Cap | 327M 287M 264M 246M 464M 31.05B 473M 3.17B 1.23B 15.24B 1.23B 1.2B 53.04B | P/E 2026 * |
-18.7x | P/E 2027 * | -14.3x |
|---|---|---|---|---|---|
| Enterprise Value | 327M 287M 264M 246M 464M 31.05B 473M 3.17B 1.23B 15.24B 1.23B 1.2B 53.04B | EV / Sales 2026 * |
18.2x | EV / Sales 2027 * | 18.1x |
| Free-Float |
95.07% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioTime, Inc.
| 1 day | +7.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 16/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 13/11/2022 |
| Chief Operating Officer | - | 30/11/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 30/06/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 10/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 26/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.37% | -11.55% | - | - | 327M | |
| +3.08% | +9.20% | -0.42% | +5.47% | 47.18B | |
| +0.12% | +10.45% | +408.29% | +598.88% | 39.82B | |
| +5.17% | +9.47% | +24.96% | -8.08% | 32.25B | |
| +2.02% | +4.91% | +18.59% | +60.76% | 31.68B | |
| +0.69% | +8.72% | +14.80% | +30.86% | 24.59B | |
| +0.40% | +12.51% | - | - | 16.57B | |
| +2.64% | +6.00% | +69.30% | +127.40% | 15.12B | |
| -0.15% | +4.94% | +13.27% | +17.71% | 13.69B | |
| -0.13% | +3.49% | +98.27% | +92.77% | 13.1B | |
| Average | +2.09% | +7.37% | +80.88% | +115.72% | 26B | |
| Weighted average by Cap. | +1.83% | +7.41% | +94.34% | +137.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.94M 15.75M 14.5M 13.51M 25.48M 1.71B 25.99M 174M 67.55M 837M 67.35M 65.89M 2.91B | 18.09M 15.89M 14.62M 13.63M 25.7M 1.72B 26.22M 176M 68.14M 844M 67.93M 66.46M 2.94B |
| Net income | -23.79M -20.89M -19.22M -17.91M -33.78M -2.26B -34.47M -231M -89.59M -1.11B -89.32M -87.39M -3.86B | -31.66M -27.8M -25.59M -23.84M -44.97M -3.01B -45.88M -308M -119M -1.48B -119M -116M -5.14B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
